(Q38840985)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

7

Peter Houghton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

8

E Anders Kolb

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

3

Sajida Piperdi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

10

Jonathan Gill

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

Michael Roth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

David M Barris

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Vicky Kuo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Stephanie Everts

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

David Geller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Thomas Hawthorne

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

25 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

published in

Pediatric Blood & Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

32-38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

22 February 2020

cites work

1 reference

New targets and approaches in osteosarcoma.

21 January 2018

1 reference

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

Antibody therapy of cancer

21 January 2018

1 reference

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

21 January 2018

1 reference

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.

21 January 2018

1 reference

Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion

21 January 2018

1 reference

Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB.

21 January 2018

1 reference

Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity

21 January 2018

1 reference

Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function

21 January 2018

1 reference

Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme

21 January 2018

1 reference

Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma

21 January 2018

1 reference

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer

21 January 2018

1 reference

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

21 January 2018

1 reference

Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, l-amino acid-defined diet, accelerates motility of hepatoma cells

21 January 2018

1 reference

Osteoactivin promotes breast cancer metastasis to bone

21 January 2018

1 reference

21 January 2018

1 reference

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

21 January 2018

1 reference

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma

21 January 2018

1 reference

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

21 January 2018

1 reference

Impairment of methotrexate transport is common in osteosarcoma tumor samples

21 January 2018

1 reference

How to assess the reliability of measurements in rehabilitation

21 January 2018

1 reference

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates

21 January 2018

1 reference

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

21 January 2018

1 reference

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

21 January 2018

1 reference

The pediatric preclinical testing program: description of models and early testing results.

21 January 2018

1 reference

Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.25688

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26305408%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference